Abstract
Purpose: Naegleria fowleri is the main etiologic agent implicated in primary amoebic meningoencephalitis (PAM). It is also known as the brain-eating amoeba because of the severe brain inflammation following infection, with a survival rate of about 5%. This review aims to identify Naegleria fowleri infections and evaluate patients’ progression. This literature review emphasizes the importance of rapid diagnosis and treatment of infected patients because only prompt initiation of appropriate therapy can lead to medical success. Compared to other articles of this kind, this one analyzes a large number of reported cases and all the factors that affected patients’ evolution. Materials and methods: Two independent reviewers used “Naegleria fowleri” and “case report” as keywords in the Clarivate Analytics—Web of Science literature review, obtaining 163 results. The first evaluation step was article title analysis. The two reviewers determined if the title was relevant to the topic. The first stage removed 34 articles, leaving 129 for the second stage. Full-text articles were evaluated after reading the abstract, and 77 were eliminated. This literature review concluded with 52 articles. Key findings: This review included 52 case report articles, 17 from the USA, eight from India, seven from China, four from Pakistan, two from the UK, and one each from Thailand, Korea, Japan, Italy, Iran, Norway, Turkey, Costa Rica, Zambia, Australia, Taiwan, and Venezuela, and Mexico. This study included 98 patients, with 17 women (17.4%) and 81 men (82.6%). The cases presented in this study show that waiting to start treatment until a diagnosis is confirmed can lead to rapid worsening and bad outcomes, especially since there is currently no drug that works very well as a treatment and the death rate is around 98%. Limitations: The lack of case presentation standardization may lead to incomplete case information in the review since the cases did not follow a writing protocol. The small number of global cases may also lead to misleading generalizations, especially about these patients’ treatment. Due to the small number of cases, there is no uniform sample of patients, making it difficult to determine the exact cause of infection.
Keywords: Naegleria fowleri, case report, contaminated water
1. Introduction
Naegleria fowleri is the main etiologic agent implicated in primary amoebic meningoencephalitis (PAM) [1]. It is also known as the brain-eating amoeba because of the severe inflammation of the brain following infection, with a survival rate of about 5% [2]. It is most commonly found in water or wet soils and grows very well on cell cultures or various artificial media [1]. Temperatures above 30 °C create a favorable environment for this amoeba, with survival and infection being impossible in the winter season [3]. However, it is not only high temperatures that can be a favorable factor but also the increased amount of suspended organic matter and sediment, which lead to poor water quality and a favorable environment for the development of amoebae [4]. This is the only amoeba species exhibiting three distinct morphologic forms: the trophozoite, flagellate, and cyst [1,5]. Naegleria fowleri enters the host’s system via the nasal tract, either by inhalation of dust-containing cysts or by aspiration of water contaminated with trophozoites or cysts. Young people are most often affected, as they are most often exposed to potentially contaminated environments [6]. The clinical course is mostly dramatic, and after an incubation period of 2 to 15 days, the disease has a sudden onset with a fulminant course toward death [7]. Since the officially recorded case of onset, contrary to the evolution of medicine, the number of cases seems to be increasing, with 381 cases reported from 1962 to 2018, originating in 33 countries [3,8]. Between 1965 and 2016, the overall number of reported PAM cases grew by 1.6% every year. During this time, the number of confirmed PAM cases grew by an average of 4.5% yearly [9]. In a 2020 study, it was reported that the worldwide prevalence of Naegleria in various water sources was 26.42%. The highest case rate was found in America, approximately 33.18%, not only due to multiple sources for possible infection, but also due to the large number of studies that have taken place in this territory [10].
This review aims to identify documented cases of Naegleria fowleri infection and analyze the evolution of patients since the time of infection. Thus, through this literature review, we want to emphasize the importance of the rapid diagnosis and treatment of infected patients since only the initiation of appropriate therapy as promptly as possible can lead to medical success. Compared to other articles of this sort, this one brings together a large number of reported cases, analyzing in detail all the aspects that had an impact on the evolution of patients infected with Naegleria fowleri.
2. Materials and Methods
The literature review was performed by two independent reviewers on the Clarivate Analytics—Web of Science platform using as keywords the association between “Naegleria fowleri” and “case report” and 163 results were obtained. The first evaluation step was to analyze the title of the articles. If the title was considered significant for the chosen topic, the two reviewers proceeded to abstract analysis. After the first stage, 34 articles were eliminated, leaving 129 articles for the second stage. After reading the abstract, the next eliminatory stage was the evaluation of full-text articles, and 77 papers were excluded. Finally, 52 articles were included in this literature review.
The inclusion criteria were English language, and case report type articles describing the cases of patients infected with Naegleria fowleri, regardless of the evolution they had after confirmation of the diagnosis. All eligible articles were included regardless of the year of publication or the age of patients included in the studies.
Exclusion criteria were articles that were written in full-text in a language other than English, articles that could not be accessed, conference presentations, abstracts, letters to the editor, books, editorial material, proceeding papers or review articles, and articles in which insufficient patient data were identified.
3. Results
The general characteristics of the cases included in our study can be observed in Table 1.
Table 1.
Characteristics of cases included in the review.
| Author, and Year | Country | Number of Cases | Sex and Age | Causes | Onset Symptoms | Diagnostic Test | Medical History |
|---|---|---|---|---|---|---|---|
| J. Apley et al. [11] | UK | 3 cases | Case 1—male, 2 years. Case 2—male, 6 years. Case 3—male, 4 years |
Case 1–3—playing with contaminated water (muddied puddle) | C1–C3: anorexia, irritability, sore throat, vomiting, headache, fever, neck pains | Cultured/wet mount from cerebrospinal fluid (CSF) | C3: 2 days before admission, he had a booster dose of diphtheria pertussis and tetanus vaccine |
| A.R. Cain et al., 1981 [12] | UK | 1 case | Female, 11 years | Contaminated pool water (indoor pool fed by natural warm spring water) |
Headache Fever Vomiting Blurred vision |
CSF | Healthy |
| AR Stevens et al., 1981 [13] | USA | 2 cases | Case 1—male, 14 years Case 2—male, 10 years |
Case 1 and 2—swimming in contaminated water (freshwater lake) | C1: headache, fever, malaise C2: headache, lethargy, anorexia |
CSF | Healthy |
| N.D.P. Barnett et al., 1996 [14] | USA | 2 case | Case 1—Female, 9 years Case 2—male, 8 month |
Case 1—Swimming in contaminated water (ditch) Case 2—baptized in contaminated water |
C1: Headache Emesis C2: emesis, fever |
C1 and C2: cranial CT scan, CSF | Healthy |
| Y. Sugita et al., 1999 [15] | Japan | 1 case | Female, 25 years | No data | Headache High fever |
CSF, cranial CT scan | Healthy |
| Jain et al., 2002 [16] | India | 1 case | Female, 26 years | No data | Headache Fever Vomiting Altered sensorium |
CSF | Healthy |
| S Shenoy et al., 2002 [17] | India | 1 case | Male, 5-month-old | Contaminated bath water | Fever Vomiting Seizures |
CSF | Healthy |
| Centers for Disease Control and Prevention (CDC), 2003 [18] | USA | 1 case | Male, 11 years | Swimming in contaminated water (local river) | Headache Emesis |
CSF and cranial MRI | Healthy |
| P.E. Cogo et al., 2004 [19] | Italy | 1 case | Male, 9 years | Swimming in contaminated river water | Fever Headache |
CSF and cranial CT | Healthy |
| D.T. Okuda et al., 2004 [20] | USA | 2 cases | Case 1—male, 5 years Case 2—male, 5 years |
Case 1—no data Case 2—contaminated water (bath water) |
C1: Headache, neck stiffness C2: fever, progressive lethargy |
CSF and cranial MRI | Healthy |
| S. Hebbar et al., 2005 [21] | India | 1 case | Male, 6 months | Contaminated bath water | Seizures Fever Lethargy Altered sensorium |
CSF | Healthy |
| J. Vargas-Zepada el al, 2005 [22] | Mexic | 1 case | Male, 10 years | Swimming in contaminated water (irrigation canal) | Severe headache Vomiting Fever |
CSF, cranial CT | Healthy |
| F. Petit et al., 2006 [23] | Venezuela | 2 cases | Case 1—male, 10 years Case 2—male, 23 years |
Swimming in contaminated water reservoir | C1: Headache Fever Vomiting C2: headache, fever, vomiting, drowsiness, behavioral disturbances |
CSF | Healthy |
| CDC, 2008 [24] | USA | 6 cases | Case 1—male, 14 years Case 2—male, 14 years Case 3—male, 11 years Case 4—male, 12 years Case 5—male, 22 years Case 6—male, 10 years |
Case 1, 3, 4, 5— swimming in contaminated lake water Case 2—swimming in multiple drainage ditches, canals, and apartment pool Case 6—swimming in a private water sports facility |
C1: severe headache, stiff neck, fever C2: ear pressure, severe headache, vomiting C3: headache, fever, nausea, vomiting, confusion C4: fever, lethargy, confusion C5: altered mental status, severe headache C6: body aches, high fever, nausea, vomiting, fainting |
CSF | Healthy |
| N. Gupta et al., 2009 [25] | India | 1 case | Male, 20 years | No association with contaminated water | Fever Headache Loss of vision Hearing loss Slurring of speech Difficulty in swallowing Retention of urine |
CSF, cranial CT scan | Tuberculosis, diabetes mellitus, hypertension, and acute leukemic leukemia. |
| T. Saleem et al., 2009 [26] | Pakistan | 2 cases | Case 1—male, 24 years Case 2—male, 30 years |
Case 1 and 2—swimming in contaminated water | C1: high fever, headache, vomiting C2: high fever, headache, agitation |
CSF and cranial CT scan | Healthy |
| S. Shakoor et al., 2011 [27] | Pakistan | 13 cases | 12/13 were male, mean age 31.0 ± 15.33 years | No exact data | Fever Headache Seizures |
CSF | Healthy |
| Khanna et al., 2011 [28] | India | 1 case | Male, 5 months | No data | Fever Decreases breastfeeding Vomiting Abnormal body movements |
CSF | Healthy |
| Gautam et al., 2012 [29] | India | 1 case | Male, 73 years | No data | Fever Neck pain Seizures Altered sensorium |
CSF and cranial CT scan | Type II diabetes mellitus, diabetic nephropathy, coronary artery disease (postangioplasty in 2005), head injury (9 years back), and CSF (cerebrospinal fluid) rhinorrhea |
| S.K. Kemble et al., 2012 [4] | USA | 1 case | Female, 7 years | Swimming in contaminated lake water | Headache Abdominal pain Neck soreness |
CSF, PCR, and CT scan | Healthy |
| J.S. Yoder et al., 2012 [30] | USA | 2 cases | Case 1—male, 28 years Case 2—female, 51 years |
Contaminated tap water utilized for sinus Irrigation | C1: severe headache, neck stiffness, back pain, vomiting C2: altered mental status, nausea, vomiting, poor appetite, fatigue, high fever |
C1: CSF, cranial CT scan, PCR C2: CSF |
C1: migraine C2: Healthy |
| Z. Movahedi et al., 2012 [31] | Iran | 1 case | Male, 5-month-old | No data | Fever Eye gaze Chills |
CSF and cranial CT scan | Healthy |
| CDC, 2013 [32] | USA | 1 case | Male, 47 years | Contaminated tap water used for daily household activities and for ablution | Headache Fever Confusion Agitation |
CSF and PCR | Healthy |
| M.Y. Su et al., 2013 [33] | Taiwan | 1 case | Male, 75 years | Swimming in contaminated pool water (hot springs) | Headache Fever Right arm myoclonic seizures |
CSF, MRI of the brain, cranial CT scan | Healthy |
| A. Sood et al., 2014 [34] | India | 1 case | Male, 6 years | Playing with contaminated water (cement tank) | Fever Headache Altered sensorium |
CSF | Healthy |
| A. Shariq et al., 2014 [35] | Pakistan | 1 case | Male, 42 years | Using contaminated water | Fever Vomiting Loose stools Behavioral disturbances |
CSF | Healthy |
| P.J. Booth et al., 2015 [36] | USA | 1 case | Male, 11 years | Swimming in contaminated pool water (resort hot springs) | Headache Fever Stiff neck Nausea Vomiting |
CSF | Healthy |
| J.R. Cope et al., 2015 [37] | USA | 1 case | Male, 4 years | Playing with contaminated pool water | Vomiting Severe headache Diarrhea Poor oral intake |
CSF and cranial CT scan | Healthy |
| R.O. Johnson et al., 2016 [38] | USA | 1 case | Female, 21 years | Swimming in contaminated spring water | Headache Nausea Vomiting |
CSF | Healthy |
| J.R. Cope et al., 2016 [39] | USA | 2 cases | Case 1—male, 12 years Case 2—male, 8 years |
Case 1—contaminated stagnant rainwater Case 2—contaminated river water |
C1: headache, weakness, vomiting, fever, altered mental status C2: fever, headache, chills, nausea, vomiting, altered mental status | C1: CSF, cranial CT scan, PCR C2: CSF |
Healthy |
| T.T. Stubhaug et al., 2016 [40] | Norway | 1 case | Female, 71 years | Contaminated tap water | Nausea, vomiting, fever, exhaustion | CSF, cranial CT scan | Healthy |
| R.C. Stowe et al., 2017 [41] | USA | 2 cases | Case 1—male, 5 years Case 2—male, 14 years |
Case 1 and 2—swimming in contaminated water | C1: fever, altered mental status, seizures C2: generalized muscle weakness, fever |
C1: CSF, cranial CT, brain MRI C2: CSF, cranial CT |
Healthy |
| J.R. Cope et al., 2017 [42] | USA | 1 case | Female, 18 years | Swimming in contaminated water | Headache Fever Lethargy |
CSF, cranial CT scan | Healthy |
| T.W. Heggie et al., 2017 [43] | USA | 1 case | Female, 12 years | Swimming in contaminated lake water | Vomiting Fever Headache |
CSF | Healthy |
| N.K. Ghanchi et al., 2017 [44] | Pakistan | 19 cases | 84% male, median age 28 years (16/19) | No exact data | Fever (63%) Altered consciousness (53%) Headache (32%) Seizures (21) Disorientation (10%) |
CSF and PCR | Healthy |
| M. Chomba et al., 2017 [45] | Zambia | 1 case | Male, 24 years | Swimming in contaminated river water | Seizures Fever |
CSF, cranial CT | Healthy |
| Q. Wang et al., 2018 [46] | China | 1 case | Male, 42 years | Contaminated water | Fever Headache |
CSF, cranial CT | Healthy |
| M. Chen et al., 2019 [47] | China | 1 case | Male, 43 years | Swimming in contaminated pool water | Headache Fever Myalgia Fatigue |
CSF, cranial CT | Healthy |
| A. McLaughlin et al., 2019 [48] | Australia | 1 case | Male, 56 years | Swimming in contaminated water/irrigation of nostrils | Headache Photophobia Nausea Vomiting Neck stiffness |
CSF, cranial CT | No data |
| L.R. Moreira et al., 2020 [49] | Costa Rica | 3 cases | Case 1—male, 15 years Case 2—female, 5 years Case 3—male, 1 year |
Case 1 and 2—contaminated pool water (hot spring resort) Case 3—contaminated bath water |
C1: general discomfort, severe headache, nausea, vomiting C2: lower limb pain, spasticity, hyperreflexia, walking difficulty, headache, vomiting, fever C3: fever, drowsiness, altered state of consciousness. |
C1: no data C2 and C3: CSF |
Healthy |
| S. Huang et al., 2021 [50] | China | 1 case | Male, 8 years | Swimming in contaminated water | Headache Vomiting Fever Disturbance of consciousness |
CSF, cranial CT scan, head and neck MRI | No data |
| Y. Celik et al., 2021 [51] | Turkey | 1 case | Male, 11 days old | Contaminated bath water | Irritability Inability to suck Fever |
CSF, cranial MRI, PCR | Healthy |
| S.K. Anjum et al., 2021 [52] | USA | 1 case | Male, 13 years | Swimming in contaminated water (water park) | Headache Fever Intractable emesis |
CSF, cranial CT scan, brain MRI, PCR | History of headache |
| P. Soontrapa et al., 2022 [53] | Thailand | 1 case | Female, 40 years | Contaminated water (she poured water from a waterfall on her head and face) |
Severe headache High fever |
CSF, cranial CT scan | No data |
| P. Maloney et al., 2022 [54] | USA | 1 case | Male, 8 years | Swimming in contaminated river water | Fever Altered mental status Malaise Headache Fatigue Decreased appetite |
CSF, cranial CT scan | Healthy |
| X. Che et al., 2023 [55] | China | 1 case | Male, 38 years | No exact data | Fever Headache Disturbance of consciousness |
CSF and cranial CT scan | No data |
| K.W. Hong et al., 2023 [8] | Korea | 1 case | Male, 52 years | No exact data | Headache Fever |
CSF and cranial CT scan | No data |
| N.N. Baqer et al., 2023 [2] | Iraq | 1 case | Female, 18 years | Contaminated river water | Fever Headache Stiff neck |
CSF, PCR, cranial CT scan | Weight-loss and malnutrition |
| F. Wang et al., 2023 [56] | China | 1 case | Male, 62 years | Contaminated water (the patient was a fisherman) | Vomiting Headache Behavior change |
CSF and cranial CT scan | No data |
| Q. Wu et al., 2024 [57] | China | 1 case | Male, 42 years | He drank tea and was washed by his mother with spring water. | High fever | CSF, cranial CT scan | The patient was bed-ridden due to a disability caused by burns |
| L. Lin et al., 2024 [58] | China | 1 case | Female, 6 year | Swimming in contaminated pool water | Fever Headache Vomiting Lethargy |
Metagenomic next-generation sequencing, CSF, PCR, cranial CT scan | Healthy |
| S.N. Puthanpurayil et al., 2024 [59] | India | 1 case | Male, 36 years | Contaminated tap water (nasal irrigation) | Seizures Altered sensorium Headache Nausea Photophobia High fever |
CSF | Healthy, 15-year-old corrected surgically nasal bone fracture |
Blood samples for biochemistry and hemogram were taken from all patients.
The evolution and treatment of the patients included in this review can be observed in Table 2.
Table 2.
Evolution and treatment of the patients included in the review.
| Author | Timeline Between Exposure and Onset of Symptoms | Timeline Between Onset of Symptoms and Presentation to Hospital | Antibiotic Treatment | Days of Hospitalization | Evolution |
|---|---|---|---|---|---|
| J. Apley et al. [11] | C1: 2 days C2: 9 days C3: 13 days |
C1: One day before admission C2: on the morning of admission C3: on the morning of admission |
Case 1—Sulfadiazine, Penicilina, Ampicilina, Amphotericin B Case 2—Sulfadiazine, Amphotericin B Case 3—Sulfadiazine, Amphotericin B Amphotericin 0.25 mg/kg/day iv. to 1 mg/kg/day iv Sulphadiazine 750 mg/6 h |
Case 1—16 days; Case 2—18 days; Case 3—24 days |
Case 1—died; Case 2—cured; Case 3—cured |
| A.R. Cain et al. [12] | 6 days | 3 days | Penicillin, Sulfadimidine, Chloramphenicol, Sulfadiazine, Metronidazole, Amphotericin B. Amphotericin B 0.5 mg to 0.6 mg/kg/day/iv Amphotericin B 0.1 mg through an intraventricular catheter |
4 days | Died |
| A.R. Stevens et al. [13] | C1: 3 weeks before C2: several days before |
C1: 2 days C2: on the day of admission into the hospital |
Case 1—Penicillin G 3 g/4 h, Amphotericin B 10 mg/day iv and 0.05 mg/day intrathecally, Miconazole 200 mg/day iv and intrathecally 20 mg/day Case 2—Penicillin 1.25 million units/6 h iv, Amphotericin B 1 mg/kg/day iv and intraventricular 0.1 mg |
Case 1 and 2—5 days | Case 1 and 2—died |
| N.D.P. Barnett et al. [14] | C1: The day after exposure C2: soon after baptized |
C1: 2 days C2: 24 h |
C1 and C2: Cefuroxime, Acyclovir No data regarding doses |
C1: 4 days C2: 3 days |
C1 and C2: Died |
| Y. Sugita et al. [15] | No data | 2 days | No data | 8 days | Died |
| Jain et al. [16] | No data | 10 days | Amphotericin B 1 mg/kg/day iv Rifampicin 450 mg/day po Ornidazole 500 mg/8 h |
28 days | Cured |
| S. Shenoy et al. [17] | No data | 1 week | Amphotericin B 0.6 mg/kg/day iv Ceftriaxone 100 mg/kg/day po |
2 days | Died |
| Centers for Disease Control and Prevention (CDC) [18] | No data | 2 days | Amphotericin B, Rifampicin, Ketoconazole | 4 days | Died |
| P.E. Cogo et al. [19] | 10 days | 1 day | Ceftriaxone, Acyclovir 0.35 g/kg/6 h | 4 days | Died |
| D.T. Okuda et al. [20] | No data | C1: no data C2: 3 days |
Case 1—no data Case 2—empiric antibiotic |
Case 1—48 h Case 2—no data |
Case 1—died Case 2—died |
| S. Hebbar et al. [21] | No data | 3 days | Amphotericin B, Chloramphenicol and Metronidazole | 10 h | Died |
| J. Vargas-Zepada et al. [22] | One week before admission into the hospital | On the day of admission into the hospital | Ceftriaxone 100 mg/kg/8 h iv, Rifampicin 10 mg/kg/24 h po and Amphotericin B 0.25 mg/kg/24 h iv (daily 0.25 mg/kg increasing dosage up to 1 mg/kg/day), Fluconazole 10 mg/kg/24 h iv | 23 days | Cured |
| F. Petit et al. [23] | C1: 5 days C2: no data |
C1: one day before admission into the hospital C2: 4 days before admission into the hospital |
Case 1—Amphotericin B Case 2—no data |
Case 1—3 days Case 2—2 days |
Case 1—died Case 1—died |
| CDC [24] | C1: 7 days C2: 2 weeks C3: 6 days C4: weeks C5: 7 days C6: 8–15 days |
C1: 2 days C2: 2 days C3: 4 days C4: 6 days C5: 2 days C6: 3 days |
Case 1—no data Case 2—no data Case 3—Amphotericin B, Fluconazole, Ceftriaxone, Azithromycin, Rifampicin Case 4—Amphotericin B, Rifampicin, Azithromycin Case 5—no data Case 6—Amphotericin B, Rifampicin, Azithromycin, Fluconazole |
Case 1—2 days Case 2—no data Case 3—3 days Case 4—5 days Case 5—5 days Case 6—3 days |
Case 1—died Case 2—died Case 3—died Case 4—died Case 5—died Case 6—died |
| N Gupta et al. [25] | No data | 2 days | Ceftriaxone, Amikacin, Amphotericin B, Rifampicin | No exact data | Died |
| T. Saleem et al. [26] | No data | C1: 2 days C2: 3 days |
Case 1—Ceftriaxone, Acyclovir, Vancomycin, Meropenem, Amphotericin B, Fluconazole, Rifampicin Case 2—Acyclovir, Ceftriaxone, Meropenem, Vancomycin, Amphotericin B, Fluconazole |
Case 1—6 days Case 2—8 days |
Case 1—died Case 2—died |
| S. Shakoor et al. [27] | No data | Mean ±SD: 2.5 ± 1.19 days | Amphotericin B (1.5 mg/kg/day/iv), Rifampin (600 mg/day), Fluconazole or Itraconazole | 6.38 ± 3.15 days | Died |
| Khanna et al. [28] | No data | 2 days | Ceftriaxone 250 mg TID and iv, Amikacin 50 mg BD Amphotericin B 3 mg iv, ceftazidime 300 mg iv |
2 days | Died |
| Gautam et al. [29] | No data | 3 days | Amphotericin B (1 mg/kg/day) and oral Rifampicin (600 mg OD) | 10 days | Cured |
| S.K. Kemble et al. [4] | 2 weeks | 5 days | Penicillin, Ceftriaxone, Vancomycin | 4 days | Died |
| J.S. Yoder et al. [30] | No data | C1: 1 day C2: 3 days |
Case 1—Ceftriaxone, Linezolid, Acyclovir, Amphotericin B, Rifampin Case 2—no data |
Case 1—4 days Case 2—5 days |
Case 1—died Case 2—died |
| Z. Movahedi et al. [31] | No data | 3 days | Rifampin 10 mg/kg orally daily, Amphotericin B 1 mg/kg/day, Ceftriaxone, Vancomycin | No exact data | Cured |
| CDC [32] | No exact data | No exact data | No data | 34 days | Died |
| M.Y. Su et al. [33] | No data | No data | Intravenous amphotericin B 50 mg/day | 21 days | Died |
| A. Sood et al. [34] | No data | No data | Intravenous amphotericin B (1 mg/kg), intravenous Fluconazole (8 mg/kg), and oral Rifampicin (10 mg/kg) for 21 days | 21 days | Cured |
| A. Shariq et al. [35] | No data | 2 days | Amphotericin-B 1.5 mg/kg iv divided in two divided doses daily plus 1.5 mg/day intrathecal |
3 days | Died |
| P.J. Booth et al. [36] | 4 days | 2 days | No data | 4 days | Died |
| J.R. Cope et al. [37] | 10 days | 1 day | Vancomycin, Ceftriaxone | 5 days | Died |
| R.O. Johnson et al. [38] | 2 weeks | 1 day | No data | 3 days | Died |
| J.R. Cope et al. [39] | No data | C1: 2 days C2: 5 days |
Case 1—Acyclovir, Amphotericin B, Fluconazole, Rifampin, Vancomycin, Ceftriaxone, Azithromycin, Miltefosine Case 2—Miltefosine |
Case 1—16 days Case 2—85 days |
Case 1—died Case 2—cured, but remains with profound persistent mental disability |
| T.T. Stubhaug et al. [40] | Approx. 12 days | 2 days | Meropenem, Vancomicin, Gentamicin | No exact data | Died |
| R.C. Stowe et al. [41] | C1: 8 days C2: 8 days |
C1: 5 days C2: 3 days |
Case 1—Azithromycin, Rifampin, Amphotericin B, Fluconazole, Miltefosine Case 2—Vancomycin, Ceftriaxone, Fluconazole, Azithromycin, Rifampin, Amphotericin, Miltefosine |
Case 1—2 days Case 2—4 days |
Case 1—died Case 2—died |
| J.R. Cope et al. [42] | Approx. 10 days | 3 days | Amphotericin B, Fluconazole, Azithromycin, Rifampin | 3 days | Died |
| T.W. Heggie et al. [43] | Few days | 2 days | Amphotericin B, Rifampin, Fluconazole, Dexamethasone, Azithromycin, Miltefosine | 55 days | Cured |
| N.K. Ghanchi et al., 2017 [44] | No data | 2–3 days | Therapeutic protocol for primary amoebic meningoencephalitis | 3–4 days | 18/19 died |
| M. Chomba et al., 2017 [45] | 2 days | 1 day | Amphotericin B 50 mg IV, Ceftriaxone 2 g/day iv | 8 days | Died |
| Q. Wang et al., 2018 [46] | 1 week | 1 day | Ceftriaxone 2 g, Meropenem, Linezolid, Amphotericin B at 50 mg/day, Fluconazole 0.4 g/day | 15 days | Died |
| M. Chen et al. [47] | No exact data | 2 days | Amphotericin B, Fluconazole | 15 days | Died |
| A. McLaughlin et al. [48] | No exact data | 36 h | Intrathecal amphotericin 1.5 mg daily, amphotericin 50 mg/12 h IV, Rifampicin 600 mg IV daily, azithromycin 500 mg IV daily, Fluconazole 800 mg IV daily | 3 days | Died |
| L.R. Moreira et al. [49] | C1: 7 days C2: 2 days C3: no exact data |
C1: no data C2: 1 day C3: 3 days |
Case 1—no data Case 2—Amphotericin B Case 3—no data |
Case 1—6 days Case 2—28 days Case 3—1 day |
Case 1—died Case 2—cured Case 3—died |
| S. Huang et al. [50] | 3 days | 1 day | Meropenem, Vancomycin, Ceftriaxone | 24 days | Died |
| Y. Celik et al. [51] | 4 days | 2 days | Ampicillin, Cefotaxime, Vancomycin, Meropenem, Amphotericin B, Fluconazole, Rifampicin, Azithromycin | Approx. 4 months | Died |
| S.K. Anjum et al. [52] | 3 days | On the day of admission into the hospital | Ceftriaxone, Acyclovir, Vancomycin, Miltefosine, Amphotericin B, Fluconazole, Rifampin, Azithromycin | 5 days | Died |
| P. Soontrapa et al. [53] | 3 days | 1 day | Ceftriaxone, Doxycycline, Amphotericin B, Rifampicin, Fluconazole, Azithromycin | 5 days | Died |
| P. Maloney et al. [54] | 5 days | 3 days | Amphotericin B, Azithromycin, Fluconazole, Rifampin | 28 h | Died |
| X. Che et al. [55] | No data | 2 days | Penicillin, Ceftriaxone | 4 days | Died |
| K.W. Hong et al. [8] | No exact data | 3 days | Vancomycin, Ceftriaxone, Ampicillin, Amphotericin B, Fluconazole, Azithromycin, Rifampicin | 13 days | Died |
| N.N. Baqer et al. [2] | No exact data | 2 days | No treatment | No data | Died |
| F. Wang et al. [56] | No exact data | 3 days | No exact data | 3 days | Died |
| Q. Wu et al. [57] | Approx. 1 week | No data | Meropenem (2000 mg/8 h), Metronidazole (500 mg/8 h), Fluconazole (800 mg/day), Piperacillin-Tazobactam | 2 days | Died |
| L Lin et al. [58] | 7 days | 14 h | Cefaclor, Meropenem, Acyclovir, Vancomycin, Amphotericin B, Rifampicin | 80 h | Died |
| S.N. Puthanpurayil et al. [59] | No data | 2 days | Ceftriaxone Acyclovir |
No exact data | Died |
This review included 52 case report articles, 17 from the USA, eight from India, seven from China, four from Pakistan, two from the UK, and one each from Thailand, Korea, Japan, Italy, Iran, Norway, Turkey, Costa Rica, Zambia, Australia, Taiwan, Venezuela, and Mexico. A total of 99 patients were included, including 17 women (17.17%) and 82 men (82.82%). (Figure 1)
Figure 1.
Geographical distribution of cases.
The patients’ ages in the study ranged from 11 days to 75 years. There were seven patients less than 1 year old, 16 patients aged between 2 and 10 years, 19 patients aged between 10 and 20 years, 13 patients aged between 21 and 40 years, and 12 patients older than 40 years. In addition, in two of the studies mentioned in the review, there were 19 and 13 patients, respectively, with a mean age of 28 and 31 ± 15.33 years, respectively. Approximately, the age at which patients are more susceptible to Naegleria fowleri infection seems to be 10–40 years.
Discussing the way of infection, in 40 of the 99 cases, no exact cause or contact with contaminated water could be established, and in only one person, no link between infection and a water source was observed. Five of the patients developed symptoms after playing in areas with contaminated water, seven after swimming in pools that were irrigated with spring water, and eight and six, respectively, after swimming in lakes or rivers. One of the patients under the age of 1 died shortly after baptism, and another after being exposed to water collected after rain. For five people, symptoms started after bathing in possibly contaminated water, and six after swimming in areas where Naegleria fowleri was found after water testing. The condition of four of the patients worsened after nasal irrigation with tap water, and of another four after using tap water for various household activities. Other sources of infection were ditch water, canal irrigation, water tanks, or water parks (Figure 2).
Figure 2.
Sources of infection.
The most common symptoms with which patients in the articles included in the review presented to the doctor were fever, headache, and vomiting, symptoms specific for meningeal inflammation. Other less common symptoms were seizures, neck stiffness, fatigue, confusion, and sensory disturbances. In most cases, no exact diagnosis was considered until the results were received. However, patients who presented with symptoms specific to meningeal irritation were given a presumptive diagnosis of viral or bacterial meningitis.
Of the 99 patients, only 11 of them survived the Naegleria fowleri infection, the mortality rate being 88.88%. (Figure 3) The hospitalization period ranged from 10 h to 4 months. Further discussion on the hospitalization period shows that the most common hospitalization period was 1–5 days (45 patients). Six patients were hospitalized for 5–10 days, 3 for 1–15 days, and 14 for more than 15 days. In one study, the hospitalization period of 13 patients was approximately 6.38 ± 3.15 days. Only one case, a 6-month-old infant, had a fulminant progression to death within 10 h.
Figure 3.
Mortality rate.
Of the patients who survived, the average age was 17.8 years and the average length of hospitalization was 29.5 days. Excluding the only elderly patient in this group (73 years), the mean age for surviving patients was 11.66 years, with a mean number of days hospitalized of 31.67. In terms of patients who did not survive, the average age was about 21 years, with a number of days of hospitalization of around 8.39 days. If we exclude the only patient who was hospitalized for 4 months, the average number of days of hospitalization becomes about 6.25 days. Thus, we could say that the patients who were cured had a much longer period of hospitalization, but also a lower average age, compared to those who did not survive the Naegleria fowleri infection.
4. Discussion
4.1. Prevention
Infection with Naegleria fowleri is often fatal, with death occurring in less than 72 h in many patients [50]. As observed in the cases included in this study, it seems that one of the most common causes of infection is contact with contaminated water. Most of the time, patients come in contact with water by swimming in lakes, rivers, or even swimming pools that are not properly sanitized [59]. With modernization, the number of cases among tourists who frequent vacation resorts that include heated swimming pools has increased. For example, a 2005 study evaluating the presence of this amoeba in tourist sites in Thailand found that Naegleria fowleri was present in about 40% of the recreational sites sampled [60]. Infection can only be prevented by avoiding these types of recreational areas because, as observed in the cases presented above, most of the hospitalized patients had a history of swimming either in unsanitized swimming ponds or in natural recreational sites such as lakes or rivers. Another method of prevention could be to avoid swallowing or mouth or nostril contact with contaminated water [43].
In the cases presented above, some of the patients came into contact with this amoeba after nasal irrigation with contaminated water; therefore, people practicing this habit should be more careful about the water they use because the olfactory mucosa is one of the entry points of the amoeba [40]. When it comes to cases of infection in newborns, parents should be cautious about the water they use for preparing milk and bathing their babies since they cannot become contaminated by swimming in potentially infectious areas, but only by contact with contaminated water through ingestion or during bathing [51]. For this reason, the diagnosis of PAM is very difficult to consider in this type of patient, thus lowering the success rate of therapy [51]. Among the six cases of children under 1 year of age included in the review, four of them mention contaminated water in which the babies were being bathed as the cause of infection.
Those most susceptible to infection with this amoeba are young people with good immunity, especially young men because they are most often involved in water recreational activities in the warm season [21,31]. As noted in our review, the average hospitalization period until patients most often progress to fatality is about 5–10 days from the onset of symptoms [31]. However the infection rate is quite low, and the incidence of the disease is very low, because rarely do people who come in contact with a potential source of infection develop the disease [47].
4.2. Diagnosis
For patients to have a favorable outcome, therapy should be started as soon as possible; for this reason, physicians should be much better informed about this infection and its signs and take it into account when patients are presented in the emergency room [22]. PAM is clinically indistinguishable from classic bacterial meningitis, which is why the amoebic etiology should be suspected whenever the presence of a pathogenic bacterium cannot be detected in the CSF. Criteria that could guide the physician toward the diagnosis of this infection could be young age, recent activity in the aquatic environment, or contact with various water sources, especially heated swimming pools, rivers, lakes, or stagnant water [3,7,31]. Even when considering possible Naegleria infection, delaying optimal medication until the diagnosis is confirmed is not an ideal option, as trophozoites in cerebrospinal fluid are detected by time-consuming methods. In most of the presented cases, patients became comatose by the time of diagnostic confirmation and under correct therapy they decompensated [47]. The methods of choice for diagnosis are evaluation of the CSF smear and brain biopsy, but in recent years, there have been studies that have shown the efficiency and rapidity of next-generation sequencing (NGS) [58]. Even so, if the Naegleria fowleri infection is not taken into account and therapy is not initiated until the results are received, the chances of survival decrease, especially as there is currently no drug with substantial therapeutic efficacy, the mortality rate being approximately 98% [55].
4.3. Treatment
Regarding treatment, active substances proven to be useful include Amphotericin B, Miconazole, Tetracycline, and Rifampicin. The drug of choice used to treat this infection is Amphotericin B, administered intravenously and intrathecally, thus ensuring an increased concentration in the cerebrospinal fluid [4]. Lately, an antiparasitic called Miltefosine has been added to the basic therapeutic regimen, together with Amphotericin B, Rifampicin, and Fluconazole, with an increased success rate [56,57]. This was validated as a therapy in 2022 after an 8-year-old child was completely cured after it was added to the therapeutic regimen. Even though Amphotericin B has proven its efficacy, the similar adverse effects with patients’ onset symptoms plus nephrotoxicity emphasize the need for a new therapy. Moreover, Miltefosine has proven to be effective when it comes to patient survival following Naegleria fowleri infection, but in most cases, patients are neurologically affected [61].
Recently, there has been increasing discussion about new nanoparticle-based therapies, which are superior to older drugs because they can cross the blood–brain barrier much more easily, without the need for an additional dose increase [61,62]. Studies show that a large amount of the drug could be administered intranasally via these nanoparticles, but the cytotoxic effects and pharmacokinetics are not fully known [63]. For example, in 2017, a study of a silver nanoparticle conjugated with Amphotericin B, Nystatin, and Fluconazole was reported, which showed in vitro efficacy against the brain-eating amoeba but showed a cytotoxic effect of up to 75% [64]. On the other hand, the 50 µM concentration of a gold nanoparticle conjugated with trans-cinnamic acid showed efficacy as high as Amphotericin B, with no signs of cell toxicity [65].
5. Conclusions
The cases presented in this review are proof that delaying therapy until the diagnosis is confirmed or even because not considering Naegleria fowleri infection can lead to a fulminant evolution with an unfortunate outcome. It is important that physicians who see patients with meningitis-specific symptoms of any cause should also consider Naegleria fowleri infection, especially in young people with a history of warm-season swimming in unhygienic, inadequately irrigated places, as prompt initiation of specific therapy may increase survival rates.
6. Limitations
Considering that the cases described did not follow a unique writing protocol, the lack of standardization of case presentation may lead to incomplete information about the cases included in the review. Moreover, the small number of cases reported at the global level may lead to misleading general conclusions, especially regarding the appropriate treatment for this type of patient. Another limitation can be considered the lack of a uniform sample of patients, due to the small number of cases; thus, conclusions about the exact cause of infection may not be clear and accurate. Moreover, the reasons why some patients are more susceptible to Naegleria fowleri infection have not yet been presented in the literature, especially since most of the patients were infected through contact with contaminated water with which many other people had previously come into contact.
Author Contributions
Conceptualization, C.R. and R.G.C.; methodology, A.O.; software, A.M.; validation, C.R., C.M.C. and M.R.R.; formal analysis, A.O.; investigation, C.R.; resources, A.M.; data curation, M.R.R.; writing—original draft preparation, C.R. and R.G.C.; writing—review and editing, M.M.L.; visualization, C.M.C.; supervision, M.M.L. All authors have read and agreed to the published version of the manuscript.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Conflicts of Interest
The authors declare no conflicts of interest.
Funding Statement
This research received no external funding.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
References
- 1.Matin A. Primary amebic meningoencephalitis: A new emerging public health threat by Naegleria fowleri in Pakistan. J. Pharm. Res. Drug Des. 2017;1:1–3. [Google Scholar]
- 2.Baqer N.N., Mohammed A.S., Al-Aboody B., Ismail A.M. Genetic Detection of Amoebic Meningoencephalitis Causing by Naegleria Fowleri in Iraq: A Case Report. Iran J. Parasitol. 2023;18:408–413. doi: 10.18502/ijpa.v18i3.13765. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Hall A.D., Kumar J.E., Golba C.E., Luckett K.M., Bryant W.K. Primary amebic meningoencephalitis: A review of Naegleria fowleri and analysis of successfully treated cases. Parasitol. Res. 2024;123:84. doi: 10.1007/s00436-023-08094-w. [DOI] [PubMed] [Google Scholar]
- 4.Kemble S.K., Lynfield R., DeVries A.S., Drehner D.M., Pomputius W.F., III, Beach M.J., Visvesvara G.S., da Silva A.J., Hill V.R., Yoder J.S., et al. Fatal Naegleria fowleri infection acquired in Minnesota: Possible expanded range of a deadly thermophilic organism. Clin. Infect. Dis. 2012;54:805–809. doi: 10.1093/cid/cir961. [DOI] [PubMed] [Google Scholar]
- 5.Zeibig E. Clinical Parasitology: A Practical Approach. 2nd ed. Elsevier Saunders; St. Louis, MO, USA: 2013. [Google Scholar]
- 6.Mahmud R., Ai Lian Lim Y., Amir A. Medical Parasitology: A Textbook. Springer; Cham, Switzerland: 2017. [Google Scholar]
- 7.Radulescu S. Parazitologie Medicala. Editura ALL Education; București, Romania: 2000. [Google Scholar]
- 8.Hong K.W., Jeong J.H., Byun J.H., Hong S.H., Ju J.W., Bae I.G. Fatal Primary Amebic Meningoencephalitis due to Naegleria fowleri: The First Imported Case in Korea. Yonsei Med. J. 2023;64:641–645. doi: 10.3349/ymj.2023.0189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Gharpure R., Bliton J., Goodman A., Ali I.K.M., Yoder J., Cope J.R. Epidemiology and Clinical Characteristics of Primary Amebic Meningoencephalitis Caused by Naegleria fowleri: A Global Review. Clin. Infect. Dis. 2021;73:e19–e27. doi: 10.1093/cid/ciaa520. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Saberi R., Seifi Z., Dodangeh S., Najafi A., Abdollah Hosseini S., Anvari D., Taghipour A., Norouzi M., Niyyati M. A systematic literature review and meta-analysis on the global prevalence of Naegleria spp. in water sources. Transbound. Emerg. Dis. 2020;67:2389–2402. doi: 10.1111/tbed.13635. [DOI] [PubMed] [Google Scholar]
- 11.Apley J., Clarke S.K., Roome A.P., Sandry S.A., Saygi G., Silk B., Warhurst D.C. Primary amoebic meningoencephalitis in Britain. Br. Med. J. 1970;1:596–599. doi: 10.1136/bmj.1.5696.596. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Cain A.R., Wiley P.F., Brownell B., Warhurst D.C. Primary amoebic meningoencephalitis. Arch. Dis. Child. 1981;56:140–143. doi: 10.1136/adc.56.2.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Stevens A.R., Shulman S.T., Lansen T.A., Cichon M.J., Willaert E. Primary amoebic meningoencephalitis: A report of two cases and antibiotic and immunologic studies. J. Infect. Dis. 1981;143:193–199. doi: 10.1093/infdis/143.2.193. [DOI] [PubMed] [Google Scholar]
- 14.Barnett N.D., Kaplan A.M., Hopkin R.J., Saubolle M.A., Rudinsky M.F. Primary amoebic meningoencephalitis with Naegleria fowleri: Clinical review. Pediatr. Neurol. 1996;15:230–234. doi: 10.1016/S0887-8994(96)00173-7. [DOI] [PubMed] [Google Scholar]
- 15.Sugita Y., Fujii T., Hayashi I., Aoki T., Yokoyama T., Morimatsu M., Fukuma T., Takamiya Y. Primary amebic meningoencephalitis due to Naegleria fowleri: An autopsy case in Japan. Pathol. Int. 1999;49:468–470. doi: 10.1046/j.1440-1827.1999.00893.x. [DOI] [PubMed] [Google Scholar]
- 16.Jain R., Prabhakar S., Modi M., Bhatia R., Sehgal R. Naegleria meningitis: A rare survival. Neurol. India. 2002;50:470–472. [PubMed] [Google Scholar]
- 17.Shenoy S., Wilson G., Prashanth H.V., Vidyalakshmi K., Dhanashree B., Bharath R. Primary meningoencephalitis by Naegleria fowleri: First reported case from Mangalore, South India. J. Clin. Microbiol. 2002;40:309–310. doi: 10.1128/JCM.40.1.309-310.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Centers for Disease Control and Prevention (CDC) Primary amebic meningoencephalitis-Georgia, 2002. Morb. Mortal Wkly. Rep. MMWR. 2003;52:962–964. [PubMed] [Google Scholar]
- 19.Cogo P.E., Scagli M., Gatti S., Rossetti F., Alaggio R., Laverda A.M., Zhou L., Xiao L., Visvesvara G.S. Fatal Naegleria fowleri meningoencephalitis, Italy. Emerg. Infect. Dis. 2004;10:1835–1837. doi: 10.3201/eid1010.040273. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Okuda D.T., Hanna H.J., Coons S.W., Bodensteiner J.B. Naegleria fowleri hemorrhagic meningoencephalitis: Report of two fatalities in children. J. Child. Neurol. 2004;19:231–233. doi: 10.1177/088307380401900301. [DOI] [PubMed] [Google Scholar]
- 21.Hebbar S., Bairy I., Bhaskaranand N., Upadhyaya S., Sarma M.S., Shetty A.K. Fatal case of Naegleria fowleri meningo-encephalitis in an infant: Case report. Ann. Trop. Paediatr. 2005;25:223–226. doi: 10.1179/146532805X58166. [DOI] [PubMed] [Google Scholar]
- 22.Vargas-Zepeda J., Gómez-Alcalá A.V., Vásquez-Morales J.A., Licea-Amaya L., De Jonckheere J.F., Lares-Villa F. Successful treatment of Naegleria fowleri meningoencephalitis by using intravenous amphotericin B, fluconazole and rifampicin. Arch. Med. Res. 2005;36:83–86. doi: 10.1016/j.arcmed.2004.11.003. [DOI] [PubMed] [Google Scholar]
- 23.Petit F., Vilchez V., Torres G., Molina O., Dorfman S., Mora E., Cardozo J. Meningoencefalitis amebiana primaria: Comunicacion de dos nuevos casos Venezolanos. Arq. de Neuro-Psiquiatria. 2006;64:1043–1046. doi: 10.1590/S0004-282X2006000600034. [DOI] [PubMed] [Google Scholar]
- 24.Centers for Disease Control and Prevention (CDC) Primary amebic meningoencephalitis-Arizona, Florida, and Texas, 2007. Morb. Mortal Wkly. Rep. MMWR. 2008;57:573–577. [PubMed] [Google Scholar]
- 25.Gupta N., Bhaskar H., Duggal S., Ghalaut P.S., Kundra S., Arora D.R. Primary amoebic meningoencephalitis: First reported case from Rohtak, North India. Braz. J. Infect. Dis. 2009;13:236–237. doi: 10.1590/S1413-86702009000300016. [DOI] [PubMed] [Google Scholar]
- 26.Saleem T., Rabbani M., Jamil B. Primary amoebic meningoencephalitis: Two new cases from Pakistan. Trop. Doct. 2009;39:242–243. doi: 10.1258/td.2009.090032. [DOI] [PubMed] [Google Scholar]
- 27.Shakoor S., Beg M.A., Mahmood S.F., Bandea R., Sriram R., Noman F., Ali F., Visvesvara G.S., Zafar A. Primary amebic meningoencephalitis caused by Naegleria fowleri, Karachi, Pakistan. Emerg. Infect. Dis. 2011;17:258–261. doi: 10.3201/eid1702.100442. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Khanna V., Khanna R., Hebbar S., Shashidhar V., Mundkar S., Munim F., Annamalai K., Nayak D., Mukhopadhayay C. Primary Amoebic Meningoencephalitis in an Infant due to Naegleria fowleri. Case Rep. Neurol. Med. 2011;2011:782539. doi: 10.1155/2011/782539. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Gautam P.L., Sharma S., Puri S., Kumar R., Midha V., Bansal R. A rare case of survival from primary amebic meningoencephalitis. Indian J. Crit. Care Med. 2012;16:34–36. doi: 10.4103/0972-5229.94432. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Yoder J.S., Straif-Bourgeois S., Roy S.L., Moore T.A., Visvesvara G.S., Ratard R.C., Hill V.R., Wilson J.D., Linscott A.J., Crager R., et al. Primary amebic meningoencephalitis deaths associated with sinus irrigation using contaminated tap water. Clin. Infect. Dis. 2012;55:79–85. doi: 10.1093/cid/cis626. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Movahedi Z., Shokrollahi M.R., Aghaali M., Heydari H. Primary amoebic meningoencephalitis in an Iranian infant. Case Rep. Med. 2012;2012:782854. doi: 10.1155/2012/782854. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Centers for Disease Control and Prevention (CDC) Notes from the field: Primary amebic meningoencephalitis associated with ritual nasal rinsing-St. Thomas, U.S. Virgin Islands, 2012. Morb. Mortal Wkly. Rep. MMWR. 2013;62:903. [PMC free article] [PubMed] [Google Scholar]
- 33.Su M.Y., Lee M.S., Shyu L.Y., Lin W.C., Hsiao P.C., Wang C.P., Ji D.D., Chen K.M., Lai S.C. A fatal case of Naegleria fowleri meningoencephalitis in Taiwan. Korean J. Parasitol. 2013;51:203–206. doi: 10.3347/kjp.2013.51.2.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Sood A., Chauhan S., Chandel L., Jaryal S.C. Prompt diagnosis and extraordinary survival from Naegleria fowleri meningitis: A rare case report. Indian J. Med. Microbiol. 2014;32:193–196. doi: 10.4103/0255-0857.129834. [DOI] [PubMed] [Google Scholar]
- 35.Shariq A., Afridi F.I., Farooqi B.J., Ahmed S., Hussain A. Fatal primary meningoencephalitis caused by Naegleria fowleri. J. Coll. Physicians Surg. Pak. 2014;24:523–525. [PubMed] [Google Scholar]
- 36.Booth P.J., Bodager D., Slade T.A., Jett S. Primary Amebic Meningoencephalitis Associated with Hot Spring Exposure During International Travel—Seminole County, Florida, July 2014. Morb. Mortal Wkly. Rep. MMWR. 2015;64:1226. doi: 10.15585/mmwr.mm6443a5. [DOI] [PubMed] [Google Scholar]
- 37.Cope J.R., Ratard R.C., Hill V.R., Sokol T., Causey J.J., Yoder J.S., Mirani G., Mull B., Mukerjee K.A., Narayanan J., et al. The first association of a primary amebic meningoencephalitis death with culturable Naegleria fowleri in tap water from a US treated public drinking water system. Clin. Infect. Dis. 2015;60:36–42. doi: 10.1093/cid/civ017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Johnson R.O., Cope J.R., Moskowitz M., Kahler A., Hill V., Behrendt K., Molina L., Fullerton K.E., Beach M.J. Notes from the Field: Primary Amebic Meningoencephalitis Associated with Exposure to Swimming Pool Water Supplied by an Overland Pipe—Inyo County, California, 2015. Morb. Mortal Wkly. Rep. MMWR. 2016;65:424. doi: 10.15585/mmwr.mm6516a4. [DOI] [PubMed] [Google Scholar]
- 39.Cope J.R., Conrad D.A., Cohen N., Cotilla M., DaSilva A., Jackson J., Visvesvara G.S. Use of the Novel Therapeutic Agent Miltefosine for the Treatment of Primary Amebic Meningoencephalitis: Report of 1 Fatal and 1 Surviving Case. Clin. Infect. Dis. 2016;62:774–776. doi: 10.1093/cid/civ1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Stubhaug T.T., Reiakvam O.M., Stensvold C.R., Hermansen N.O., Holberg-Petersen M., Antal E.A., Gaustad K., Førde I.S., Heger B. Fatal primary amoebic meningoencephalitis in a Norwegian tourist returning from Thailand. JMM Case Rep. 2016;3:e005042. doi: 10.1099/jmmcr.0.005042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Stowe R.C., Pehlivan D., Friederich K.E., Lopez M.A., DiCarlo S.M., Boerwinkle V.L. Primary Amebic Meningoencephalitis in Children: A Report of Two Fatal Cases and Review of the Literature. Pediatr. Neurol. 2017;70:75–79. doi: 10.1016/j.pediatrneurol.2017.02.004. [DOI] [PubMed] [Google Scholar]
- 42.Cope J.R., Murphy J., Kahler A., Gorbett D.G., Ali I., Taylor B., Corbitt L., Roy S., Lee N., Roellig D., et al. Primary Amebic Meningoencephalitis Associated with Rafting on an Artificial Whitewater River: Case Report and Environmental Investigation. Clin. Infect. Dis. 2018;66:548–553. doi: 10.1093/cid/cix810. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Heggie T.W., Küpper T. Surviving Naegleria fowleri infections: A successful case report and novel therapeutic approach. Travel. Med. Infect. Dis. 2017;16:49–51. doi: 10.1016/j.tmaid.2016.12.005. [DOI] [PubMed] [Google Scholar]
- 44.Ghanchi N.K., Jamil B., Khan E., Ansar Z., Samreen A., Zafar A., Hasan Z. Case Series of Naegleria fowleri Primary Ameobic Meningoencephalitis from Karachi, Pakistan. Am. J. Trop. Med. Hyg. 2017;97:1600–1602. doi: 10.4269/ajtmh.17-0110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Chomba M., Mucheleng’anga L.A., Fwoloshi S., Ngulube J., Mutengo M.M. A case report: Primary amoebic meningoencephalitis in a young Zambian adult. BMC Infect. Dis. 2017;17:532. doi: 10.1186/s12879-017-2638-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Wang Q., Li J., Ji J., Yang L., Chen L., Zhou R., Yang Y., Zheng H., Yuan J., Li L., et al. A case of Naegleria fowleri related primary amoebic meningoencephalitis in China diagnosed by next-generation sequencing. BMC Infect. Dis. 2018;18:349. doi: 10.1186/s12879-018-3261-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Chen M., Ruan W., Zhang L., Hu B., Yang X. Primary Amebic Meningoencephalitis: A Case Report. Korean J. Parasitol. 2019;57:291–294. doi: 10.3347/kjp.2019.57.3.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.McLaughlin A., O’Gorman T. A local case of fulminant primary amoebic meningoencephalitis due to Naegleria fowleri. Rural Remote Health. 2019;19:4313. doi: 10.22605/RRH4313. [DOI] [PubMed] [Google Scholar]
- 49.Retana Moreira L., Zamora Rojas L., Grijalba Murillo M., Molina Castro S.E., Abrahams Sandí E. Primary Amebic Meningoencephalitis Related to Groundwater in Costa Rica: Diagnostic Confirmation of Three Cases and Environmental Investigation. Pathogens. 2020;9:629. doi: 10.3390/pathogens9080629. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Huang S., Liang X., Han Y., Zhang Y., Li X., Yang Z. A pediatric case of primary amoebic meningoencephalitis due to Naegleria fowleri diagnosed by next-generation sequencing of cerebrospinal fluid and blood samples. BMC Infect. Dis. 2021;21:1251. doi: 10.1186/s12879-021-06932-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Celik Y., Arslankoylu A.E. A Newborn with Brain-Eating Ameba Infection. J. Trop. Pediatr. 2021;67:fmaa100. doi: 10.1093/tropej/fmaa100. [DOI] [PubMed] [Google Scholar]
- 52.Anjum S.K., Mangrola K., Fitzpatrick G., Stockdale K., Matthias L., Ali I.K.M., Cope J.R., O’Laughlin K., Collins S., Beal S.G., et al. A case report of primary amebic meningoencephalitis in North Florida. ID Cases. 2021;25:e01208. doi: 10.1016/j.idcr.2021.e01208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Soontrapa P., Jitmuang A., Ruenchit P., Tiewcharoen S., Sarasombath P.T., Rattanabannakit C. The First Molecular Genotyping of Naegleria fowleri Causing Primary Amebic Meningoencephalitis in Thailand with Epidemiology and Clinical Case Reviews. Front. Cell Infect. Microbiol. 2022;12:931546. doi: 10.3389/fcimb.2022.931546. Erratum in Front. Cell Infect. Microbiol. 2022, 12, 1021158. https://doi.org/10.3389/fcimb.2022.1021158 . [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Maloney P., Mowrer C., Jansen L., Karre T., Bedrnicek J., Obaro S.K., Iwen P.C., McCutchen E., Wetzel C., Frederick J., et al. Fatal Primary Amebic Meningoencephalitis in Nebraska: Case Report and Environmental Investigation, August 2022. Am. J. Trop. Med. Hyg. 2023;109:322–326. doi: 10.4269/ajtmh.23-0211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Che X., He Z., Tung T.H., Xia H., Lu Z. Diagnosis of primary amoebic meningoencephalitis by metagenomic next-generation sequencing: A case report. Open Life Sci. 2023;18:20220579. doi: 10.1515/biol-2022-0579. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Wang F., Shen F., Dai W., Zhao J., Chen X., Liu J. A primary amoebic meningoencephalitis case associated with swimming in seawater. Parasitol. Res. 2023;122:2451–2452. doi: 10.1007/s00436-023-07934-z. [DOI] [PubMed] [Google Scholar]
- 57.Wu Q., Chen C., Li J., Lian X. Primary Amebic Meningoencephalitis Caused by Naegleria fowleri in China: A Case Report. Infect. Microbes. Dis. 2024;6:43–45. doi: 10.1097/IM9.0000000000000141. [DOI] [Google Scholar]
- 58.Lin L., Luo L., Wu M., Chen J., Liao Y., Zhang H. Utilizing metagenomic next-generation sequencing and phylogenetic analysis to identify a rare pediatric case of Naegleria fowleri infection presenting with fulminant myocarditis. Front. Microbiol. 2024;15:1463822. doi: 10.3389/fmicb.2024.1463822. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Puthanpurayil S.N.T., Mukundan A., Nair S.R., John A.P., Thampi M.R., John R., Sehgal R. Free-living amoebic encephalitis—Case series. Trop. Parasitol. 2024;14:108–112. doi: 10.4103/tp.tp_37_23. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Lekkla A., Sutthikornchai C., Bovornkitti S., Sukthana Y. Free-living ameba contamination in natural hot springs in Thailand. Southeast Asian J. Trop. Med. Public Health. 2005;36:5–9. [PubMed] [Google Scholar]
- 61.Güémez A., García E. Primary Amoebic Meningoencephalitis by Naegleria fowleri: Pathogenesis and Treatments. Biomolecules. 2021;11:1320. doi: 10.3390/biom11091320. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Rajendran K., Anwar A., Khan N.A., Aslam Z., Raza Shah M., Siddiqui R. Oleic Acid Coated Silver Nanoparticles Showed Better in Vitro Amoebicidal Effects against Naegleria fowleri than Amphotericin B. ACS Chem. Neurosci. 2020;11:2431–2437. doi: 10.1021/acschemneuro.9b00289. [DOI] [PubMed] [Google Scholar]
- 63.Fong H., Leid Z.H., Debnath A. Approaches for Targeting Naegleria fowleri Using Nanoparticles and Artificial Peptides. Pathogens. 2024;13:695. doi: 10.3390/pathogens13080695. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Rajendran K., Anwar A., Khan N.A., Siddiqui R. Brain-Eating Amoebae: Silver Nanoparticle Conjugation Enhanced Efficacy of Anti-Amoebic Drugs against Naegleria fowleri. ACS Chem. Neurosci. 2017;8:2626–2630. doi: 10.1021/acschemneuro.7b00430. [DOI] [PubMed] [Google Scholar]
- 65.Rajendran K., Anwar A., Khan N.A., Shah M.R., Siddiqui R. trans-Cinnamic Acid Conjugated Gold Nanoparticles as Potent Therapeutics against Brain-Eating Amoeba Naegleria fowleri. ACS Chem. Neurosci. 2019;10:2692–2696. doi: 10.1021/acschemneuro.9b00111. [DOI] [PubMed] [Google Scholar]



